linjc16/ctgov huggingface dataset:
Platelet Reactivity After Receiving Clopidogrel Among Moderate CKD Patients Undergoing PCI

Study Overview
=================
Brief Summary
-----------------
Dual antiplatelet therapy (DAPT) with standard doses of aspirin and clopidogrel has long been the cornerstone in patients undergoing percutaneous coronary intervention (PCI). However, inhibition of platelet activation and aggregation after DAPT varies greatly among patients. Some clinical studies have demonstrated that patients with high on-treatment platelet reactivity are at increased risk of major adverse cardiovascular events. Tailored antiplatelet therapy seems offer an opportunity to improve outcomes after coronary stenting by drug adjustment based on platelet function testing. Unfortunately, the results of 3 major prospective trials (GRAVITAS, ARCTIC, TRIGGER PCI) of personalized antiplatelet therapy are neutral. In these studies, platelet function was only assessed by a single measurement and a single method early after the start of antiplatelet treatment. To test the stability of platelet reactivity measurements over time among patients undergoing PCI, investigators use 3 methods (VerifyNow P2Y12 assay, Flow cytometric assessment of the phosphorylation status of VASP, light transmittance aggregometry) for platelet function testing in 2 periods ( 14days), with maintenance doses of clopidogrel.

Official Title
-----------------
Platelet Reactivity Over Time After Receiving Clopidogrel Among Moderate CKD Patients Undergoing Percutaneous Coronary Intervention

Conditions
-----------------
Coronary Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. >18 years old. 2.15 ≤ eGFR < 60 ml/min/1.73 m2. 3. Clinically stable and following PCI between 4 weeks and 1 year. 4. On clopidogrel (75mg/d) and aspirin (100mg/d) treatment at least 4 weeks. Exclusion Criteria: Conditions that alter platelet function. Conditions that increase bleeding risk.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Moderate CKD Patients Undergoing PCI<br> | |
| Normal renal function Patients Undergoing PCI<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Individual Platelet Reactivity Measured by VerifyNow P2Y12 Assay Over Time after Receiving Clopidogrel among Moderate CKD Patients Undergoing Percutaneous Coronary Intervention -- A Cross-Sectional Study |  | up to 6 months |
FMRI in Monitoring Intracerebral Stem Cell Implantation for Chronic Stroke Patients

Study Overview
=================
Brief Summary
-----------------
A growing number of studies highlight the potential of stem cell transplantation as a novel therapeutic approach for stroke in animal model. But the stem cell therapy for chronic stroke patients has not been well investigated yet. In this study, the investigators will test the hypothesis that intracerebral peripheral blood hematopoietic stem cell (CD34+) (PBSC) transplantation induces neuroplasticity in chronic stroke patients. The remyelination of corticospinal tract in the lesion side, focal increased perfusion and increased cortical activity in the peri-infarcted area will be monitored by the functional MRI after stem cell therapy. The investigators study is aimed to find the potential mechanisms of the functional recovery after stem cell implantation. The investigators also hope to find image surrogate markers for prediction of patient outcome. The possible surrogate markers will be helpful in improving the treatment procedure and patient selection.

Conditions
-----------------
Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Old stroke half an year  3 year One-sided MCA infarction NIHSS stroke scale: 9-20 Exclusion Criteria: Pacemaker Cerebral aneurysm clips Neurostimulator Metallic heart valves IUD Joint replacement Metal plates Bone or joint pins Vena cava filters Embolization coils Cochlear implants Greenfieid filer Seizures Claustrophobia Bullet/gunshot Prosthesis (non-removeable) Artificial limbs (non-removeable) Surgical slips Metal screws or pins> Shrapnel/metallic fragments Harrington rod Insulin pump Ever had metal removed from in or around the eye Ever been metal worker (i.e., welder, machinist) Non-removeable hearing aids Birdnest or Gianturco filter Pregnant

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stroke, stem cell
Cardiopulmonary Rehabilitation in Chronic Stroke

Study Overview
=================
Brief Summary
-----------------
This study is aimed to determine the effects of an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program on the quality of life, care-giver burden and overall well-being of the patients.

Official Title
-----------------
Cardiopulmonary Rehabilitation in Chronic Stroke Patients

Conditions
-----------------
Stroke, Hemiplegia

Intervention / Treatment
-----------------
* Other: cardiopulmonary rehabilitation plus neurorehabilitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A history of ischemic stroke at least 6 months ago Exclusion Criteria: any cardiac or pulmonary problem that renders the patient unavailable for the program mental impairment not being able to perform exercise testing not being able to walk independently

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Study Group<br>cardiopulmonary rehabilitation plus neurorehabilitation | Other: cardiopulmonary rehabilitation plus neurorehabilitation<br>* Patients with stroke will undergo an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VO2max | Maximum oxygen consumption | 2 months |
Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the splenic activation in hypertensive patients, as compared to normotensives, using FDG-PET/CT imaging. Moreover, the investigators will investigate whether the splenic metabolic activity relates to the expression of circulating inflammatory proteins (high-sensitivity C-reactive protein [hsCRP]), interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a) or to immune profiles of activated T cells.

Official Title
-----------------
Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Other: PET/CT scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: absence of prior cancer diagnosis or remission from cancer at the time of FDG-PET/CT imaging (from at least 6 months) age ≥ 30 and ≤ 85 years absence of acute cardio/cerebrovascular disease (myocardial infarction, stroke, transient ischemic attack, revascularization) absence of acute or chronic inflammatory or autoimmune disease diagnosis of presence/absence of hypertension, on the basis of documented medical history Exclusion Criteria: diabetes atrial fibrillation use of anti-inflammatory drugs in the week preceding the FDG-PET/CT imaging chronic use of anti-inflammatory drugs

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normotensive<br>Normotensive subjects | Other: PET/CT scan<br>* PET/CT scan<br>|
| Hypertensive<br>Hypertensive subjects | Other: PET/CT scan<br>* PET/CT scan<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Splenic metabolic activity | 18FDG uptake in splenic tissue | At enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Circulating pro-inflammatory markers | Serum levels of pro-inflammatory cytokines | At enrollment |
The Effect of Wound Edge Eversion on Cosmesis

Study Overview
=================
Brief Summary
-----------------
Aesthetic appearance of repaired incisions is very important to surgical patients. It has been stated that if the edges of a wound are closed in such a manner that will result in eversion, or pouting of the edges that the end cosmetic result will be superior when compared to wound edges that are simply approximated. The purpose of this study is to compare cosmetic outcomes of incisions that are closed with everted edges to those in which the edges are simply approximated.

Detailed Description
-----------------
Surgical incisions will be split into two halfs and each half will be randomized to standard or everting sutures. 3 months later the cosmetic outcome of the healed wounds will be determined using a validated scar evaluation scale.

Official Title
-----------------
The Effect of Wound Edge Eversion on Cosmesis

Conditions
-----------------
Surgical Incisions

Intervention / Treatment
-----------------
* Procedure: Eversion
* Procedure: Approximation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age over 18. able to consent. scheduled for elective plastic or cardiothoracic surgery. Exclusion Criteria: history of keloids, hypertrophic scarring, diabetes, or peripheral vascular disease. those requiring systemic steroids or undergoing chemotherapy, and those unable or unwilling to consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Procedure: Eversion<br>* Surgical incisions will be closed in such a manner so as to evert the wound edges.<br>* Other names: mattress sutures;|
| Active Comparator: 2<br> | Procedure: Approximation<br>* Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.<br>* Other names: simple suture;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cosmetic result of surgical incision as measured by VAS scale |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cosmetic Results as measured by the Stony Brook Scar Scale |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
wound edge eversion, cosmetic outcomes, surgical incisions
Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination of indinavir (IDV) plus stavudine (d4T) plus lamivudine (3TC) to HIV-infected children. IDV will be given either as a powder mixed into applesauce or as capsules given on an empty stomach.

Detailed Description
-----------------
In this multicenter, open-label study patients receive a combined drug regimen of indinavir, stavudine, and lamivudine over 48 weeks. Patients are evaluated at Weeks 0, 2, 4, every 4 weeks until Week 24, and every 8 weeks thereafter until study completion. [AS PER AMENDMENT 4/27/99: The study has been extended for an additional 48 weeks for a total of 96 weeks.]

Official Title
-----------------
A Multicenter, Open-Labeled, 96-Week Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Indinavir in Combination With Stavudine and Lamivudine in Pediatric Patients With HIV-1 Infection

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Indinavir sulfate
* Drug: Lamivudine
* Drug: Stavudine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Your child may be eligible for this study if he/she: Is 3 - 15 years old and has consent of a parent or legal guardian who is able to return with the child for follow-up visits. Is HIV-positive. Is generally healthy. Is able to swallow medication in capsule form. Has never taken d4T or has never taken 3TC. Agrees to use barrier methods of birth control (such as condoms) during the study. The pill is not allowed during the study. Exclusion Criteria Your child will not be eligible for this study if he/she: Has a serious infection at the time of study entry. Has a history of severe diarrhea. Is unable to take any of the medications in this study for any reason. Has a history of certain serious illnesses. Has taken any protease inhibitors (PIs). Has taken any non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz (EFV), within 2 weeks prior to study entry. Has taken certain medications. Is pregnant or breast-feeding.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Indinavir sulfate|nan|
|Drug: Lamivudine|nan|
|Drug: Stavudine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dose-Response Relationship, Drug, Drug Therapy, Combination, Stavudine, HIV Protease Inhibitors, Lamivudine, Indinavir, RNA, Viral, Reverse Transcriptase Inhibitors, Viral Load
The Roles of Age, Comorbidity, and Telomere Length in Lung Cancer Treatment and Prognosis

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that the age-adjusted telomere length in lung cancer patients before chemotherapy may be correlated to comorbidity status and predict outcome. The change of telomere length shortening after chemotherapy may relate to treatment side effect and treatment response.

Detailed Description
-----------------
Except chemotherapy, telomere shortening were also related to a variety of cellular stress, including hydrogen peroxide, UV, and x-irradiation, transforming growth factor-beta, overexpression of oncogenes such as Ha-Ras. The cellular stress induced telomere shortening and/or telomere dysfunction and promote accelerated senescence in normal and malignant cells. Oxidative stress, which presented in several chronic inflammatory diseases, such as atherosclerosis, coronary artery disease, and chronic obstructive airway disease, was also found to be correlated with telomere shortening.

Official Title
-----------------
The Roles of Age, Comorbidity, and Telomere Length in Lung Cancer Treatment and Prognosis

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are newly diagnosed as lung cancer and prepared for scheduled chemotherapy. The diagnosis is based on pathology via surgical specimen, or biopsy; or cytology via lung, lymph node aspiration or effusion study. Exclusion criteria: includes clinical diagnosis of lung cancer without pathology or cytology proving, combined with other type malignancy, and expected short survival time less than one month.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The correlation between telomere length shortening and cancer treatment outcome | The clinical data, including age, gender, clinical presentation, performance status, disease stage at diagnosis, initial treatment modality, progression-free survival of initial treatment, and survival duration will be recorded. Blood sample collection, quality of life, and cognitive function assessment will be performed before chemotherapy, one and four weeks after initial chemotherapy for telomere length measurement. Telomere length is measured by quantitative polymerase chain reaction(qPCR). Patients' characteristics are compared with chi-square test. Progression-free survival and survival time are analyzed by Kaplan-Meier with log rank test. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung cancer, telomere length, comorbidity, Eastern Cooperation Oncology Group (ECOG), chemotherapy
Breastfeeding Rates at the Department of Neonatology of University Hospital Cologne

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to measure the breastfeeding success for all preterm and term newborns in our department of neonatology during the hospital stay and at the age of six months.

Detailed Description
-----------------
A score was established which combines information on breastfeeding rate and breastmilk feeding rate, and used to monitor daily breastfeeding success.

Official Title
-----------------
Prospective Inquiry of Breastfeeding Success at the Department of Neonatology of University Hospital of Cologne and Analysis of Influencing Factors

Conditions
-----------------
Newborn

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inborn or referred to our Department of Neonatology in the first week of life Informed consent of both parents or legal guardian Exclusion Criteria: No informed consent of parent or legal guardian.

Ages Eligible for Study
-----------------
Maximum Age: 7 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Breastfeeding Rate | A score was established wich combines informations on breastfeeding rate and breastmilk rate into one value. Of special interest was the score at discharge from the neonatologic center. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breastfeeding rate, preterm infant, neonatal intensive care unit
Effect of Inadequate Bowel Preparation on Urgent Colonoscopy in Patients With PPB.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to explore the effect of abbreviated bowel preparation on repeated colonoscopy in patients with PPB.

Official Title
-----------------
Effect of Inadequate Bowel Preparation on Urgent Colonoscopy in Patients With Post-polypectomy Bleeding (PPB): A Descriptive Study

Conditions
-----------------
Post-polypectomy Bleeding, Bowel Preparation, Urgent Colonoscopy

Intervention / Treatment
-----------------
* Behavioral: Bowel preparation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with bleeding after polypectomy patients treated with colonoscopy within 24 hours after bleeding patients who did not receive adequate bowel preparation (oral laxatives). Exclusion Criteria: patients whose main outcome indicators were not clearly described patients whose baseline characteristics were missing.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Bowel preparation|Observe patients who undergo bowel preparation by enema or irrigation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic rate | the rate of identified the origin of the bleeding | 1 Day of colonoscopy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ileocaecal intubation rate | the rate of colonoscopy entering the cecum | 1 Day of colonoscopy |